Noctrix Health

Noctrix Health is a private, commercial-stage medical device company based in San Jose, California, founded in 2018. The company has successfully developed and launched Nidra, an FDA-authorized wearable neuromodulation device for treating Restless Legs Syndrome (RLS), supported by pivotal clinical trial data published in a peer-reviewed journal. With recent CMS reimbursement codes, a $33.5M financing round, and inclusion in AASM clinical guidelines, Noctrix is positioned for U.S. commercialization growth while potentially expanding its technology platform to other chronic neurological disorders.

Wearable neuromodulation platform delivering Tonic Motor Activation (TOMAC) therapy via non-invasive electrical stimulation to peripheral nerves and muscles.

Nidra competes primarily against pharmaceutical treatments for RLS (dopamine agonists, alpha-2-delta ligands) and other non-drug approaches like compression devices. Its primary differentiation is its FDA-authorized, prescription-grade wearable neuromodulation mechanism, supported by Level 1 clinical evidence and formal reimbursement, positioning it as a novel non-pharmacologic standard of care option.